The Effect of COVID-19 Infection on Post-operative Complications

Sponsor
Xijing Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05677815
Collaborator
(none)
5,000
1
12
418.1

Study Details

Study Description

Brief Summary

We did an multi-centre, observational cohort study in patients who had surgery in 2023. We included participants who underwent surgery after the COVID-19 to lift the lockdown in China. Patients meeting the same criteria were eligible who had been treated during the same calendar period of 2019 through 2021. The primary outcomes were the post-operative in-hospital complications. We hypothesized that the post-operative in-hospital complications during the COVID-19 to lift the lockdown period in China were different to complications for the same kind of patients during the same calendar period of the previous years.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Underwent Surgery from 2019 to 2022

Detailed Description

The outbreak of COVID-19 and its global pandemic have posed a threat to public health. The deadly virus, SARS-CoV-2, has been evolving to new, more infectious variant and other lineages with additional immune escape mutations. The highly transmissible Omicron variant has been present for around one year and has supplanted Delta as the leading strain in the global pandemic. Despite the fact that 656 million people have been infected with SARS-CoV-2 worldwide as of January 1, 2023, asymptomatic infections and mild cases account for more than 90% because of its notably declined pathogenicity.As of December 20, 2022, more than 130 sub-branches of Omicron have been imported into China, with BA.5.2 and BF.7 being the most prevalent strains.

On December 7, 2022, the State Council of China issued an announcement on further optimization of measures for preventing and controlling the COVID-19 epidemic ( easing of rigorous "zero COVID" policies). Since then, the rapid spread of COVID-19 has caused a surge of COVID-19 infections in the majority of China. As of January 6, a total of 503302 individuals have been infected. Consequently, the proportion of surgical patients with current or previous SARS-CoV-2 infections will inevitably increase within a short period of time. It has been reported that recovery from SARS-CoV-2 infection is associated with a transiently elevated risk of postoperative complications. The longer the time interval between SARS-CoV-2 infection and surgery, the lower the risk of postoperative complications. An updated recommendation suggested postponing surgery for at least seven weeks following SARS-CoV-2 infection, thereby reducing the risk of postoperative complications and 30-day mortality to baseline levels (similar risk with patients without a history of SARS-CoV-2 infection). However, these recommendations were based on limited data from the earlier Covid-19 pandemic (mostly caused by the Delta strain) in Europe and the United States It may not be feasible to generalize and apply this experience and consensus to the Chinese population and use it to guide current practice.

In this prospective cohort study, the postoperative complications will be described and compared in patients with or without Covid-19 infection. In addition, risk factors in the patients and surgical levels that are associated with an increase in postoperative morbidities and mortalities will be assessed.

Study Design

Study Type:
Observational
Anticipated Enrollment :
5000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Effect of COVID-19 Infection on Post-operative Complications in Patients Underwent Surgery During the COVID-19 to Lift the Lockdown in China: Cohort Stdy
Actual Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
patients with COVID-19 infection underwent surgery in 2023

Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional

Procedure: Underwent Surgery from 2019 to 2022
Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional, or local anaesthesia

patients without COVID-19 infection underwent surgery in 2023

Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional

Procedure: Underwent Surgery from 2019 to 2022
Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional, or local anaesthesia

Outcome Measures

Primary Outcome Measures

  1. Post-operative complications [postoperative in-hospital or 7-day complication]

    Any postoperative in-hospital or 7-day complications, were based on the Clavien-Dindo Classified, and more than 0 grade was defined as complication.

Secondary Outcome Measures

  1. Severe post-complications [postoperative in-hospital or 7-day complication]

    The complications classified greater than Clavien-Dindo II were defined as severe; ie, any complications that led to a reintervention (III), a life-threatening organ dysfunction (IV), or death (V).

  2. in-hospital mortality [postoperative in-hospital or 7-day complication]

    The proportion of patients who died during hospitalization post-operatively.

  3. Critical care admission [postoperative in-hospital or 7-day complication]

    The proportion of patients who admitted to ICU post-operatively.

  4. Duration post-operative hospital stay [postoperative in-hospital or 7-day complication]

    The time from end of operation to discharge from hospital

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Underwent surgery at Xijing Hospital after the COVID-19 to lift the lockdown in China, effective as of 29th December in 2022 to 7th January in 2023.
Exclusion Criteria:
  • Patients who had missing primary information data (i.e., postoperative information).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Xijing Hospital Xi'an Shaanxi China 710032

Sponsors and Collaborators

  • Xijing Hospital

Investigators

  • Principal Investigator: Chong Lei, Xijing Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
chonglei, Principal Investigator, Xijing Hospital
ClinicalTrials.gov Identifier:
NCT05677815
Other Study ID Numbers:
  • KY20232002
First Posted:
Jan 10, 2023
Last Update Posted:
Jan 18, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by chonglei, Principal Investigator, Xijing Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 18, 2023